Dr Alasdair Naylor, who previously worked for the US pharmaceutical company Pfizer at their European Research and Development Headquarters in the UK, has taken up the post of Head of Research while Dr. Marie Lossky, former Licensing Manager at Partners HealthCare, has been appointed to the new post of Director of Business Development and Intellectual Property.
During his 18 year tenure with Pfizer Dr Naylor worked on a number of drug discovery and development projects and was, most recently, research head of their genitourinary therapeutic area. A neuroscientist by training, Naylor gained a BSc in Pharmacology from Aberdeen University and a PhD in Neuroscience from the University of Calgary.
Dr Lossky most recently led a team of licensing professionals within the Research Ventures and Licensing group at Partners HealthCare, the parent organization of Massachusetts General Hospital, the Brigham and Women’s Hospital, and other Harvard-affiliated medical institutions. . A molecular biologist by training, Dr. Lossky gained a Bachelor’s degree in Biochemistry and Molecular Biology from Harvard University and a PhD in Biochemistry from Imperial College, London.
Dr Eliot Forster, Solace CEO was delighted at the appointment of two such highly respected scientists:
‘I am thrilled that Al and Marie have decided to join us. We have a number of promising projects within the company. With Al and Marie’s knowledge and experience on board I firmly believe that we have a world-class team and I am confident we will deliver exceptional new medicines for the treatment of pain.’
Speaking about their new appointments Drs Naylor and Lossky were equally enthusiastic. Al Naylor stated:
‘I am delighted to take up the research head position at Solace. Approximately one in six adults in the US and Europe suffer from chronic pain and Solace is developing innovative therapies based on groundbreaking scientific discoveries in pain biology. Pain is a real area of unmet need and Solace’s exceptional combination of cutting-edge science coupled with deep clinical experience means that we are uniquely well placed to tackle this problem.’
Dr Lossky looked ahead to exciting future developments:
‘I am thrilled with this opportunity to take exceptionally promising new biology through to the clinic. Solace is built on an outstanding mix of science, genuine unmet medical need and commercial potential. The company has a number of promising projects in both pre-clinical and clinical development and I am very excited to become the latest member of what is already an exceptionally talented team.’
About Solace(TM) Pharmaceuticals Solace's mission is to establish itself as a world leader in the discovery and development of innovative therapies for pain through in-house drug discovery and development programs and selected partnerships. The current development activities of Solace focus on chronic pain, a market expected to grow substantially over the next decade, including building on the recent discovery linking BH4 to chronic pain. For all business development enquiries, please contact Eliot Forster at eliotforster@solacepharma.com or Marie Lossky at mlossky@solacepharma.com For all PR enquiries, please contact:
email :: judith.keenan@thewowfactory.co.uk Web :: www.thewowfactory.co.uk